← Back to Search

Enhanced CHW Intervention for Lung Cancer

N/A
Waitlist Available
Research Sponsored by University of Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at baseline visit
Awards & highlights

Study Summary

This trial will test the feasibility of using community health workers to help high-risk/low-resource women take steps to consult with a doctor, schedule screening, and/or attend screening for lung cancer.

Eligible Conditions
  • Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after intervention completion, at the 45-day follow up call
This trial's timeline: 3 weeks for screening, Varies for treatment, and after intervention completion, at the 45-day follow up call for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Evaluation of Efficacy - number of participants who engaged in a referred screening service
Feasibility of Implementation - screening adherence with Community Health Worker
Feasibility of Recruitment - Degree of Agreement Measured with Likert Scale

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Enhanced CHW InterventionExperimental Treatment1 Intervention
After 1:1 randomization, 30 women will additionally receive a 6-hour four week Enhanced CHW Intervention (E-CHW-I) modelled on successful peer-partnered interventions and informed by Stages of Change theory, which will add to the SI, calls and texts (if appropriate) to help problem solve and encourage screening receipt and transportation to the screening (if needed);
Group II: Standard Intervention(SI)Active Control1 Intervention
the HealthStreet Standard Intervention to include a CHW referral to an accessible and acceptable lung cancer screening site to include a financial counselor (if needed), tobacco cessation and quit resources (if still smoking) and, additionally, will watch the Genentech lung cancer screening video with the CHW;
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Enhanced CHW Intervention
2021
N/A
~50

Find a Location

Who is running the clinical trial?

University of FloridaLead Sponsor
1,340 Previous Clinical Trials
715,650 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment available to subjects at this time?

"Affirmative. The clinicaltrials.gov portal indicates that this research is actively seeking volunteers, having been first posted on April 19th 2021 and recently updated November 22nd of the same year. Sixty participants need to be enrolled at a single site."

Answered by AI

Is it possible for individuals aged fifty and over to participate in this clinical experiment?

"This research endeavor has a strict inclusion criteria that mandates participants be between 50 to 80 years old. There are 45 studies available for minors and 1628 trials focusing on elderly patients."

Answered by AI

What criteria must prospective participants meet to be eligible for this research endeavor?

"This clinical study seeks 60 individuals aged between 50 and 80 who have been diagnosed with lung cancer. Additionally, female participants must be within the same age range, possess a minimum of 20 pack-years of smoking history, live no further than 45 miles from UF Health Shands Hospital or reside in Duval County - specifically those enrolled in the 12,000+ cohort at HealthStreet."

Answered by AI

What is the current cohort size of this clinical investigation?

"Affirmative. According to the clinicaltrials.gov records, this medical trial is at present enrolling candidates since April 19th 2021 and was last modified on November 22nd 2021. The study requires 60 individuals from a single site for completion."

Answered by AI
~11 spots leftby Apr 2025